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Airway tolerance is a specialized immunological surveillance which is activated by the cells
of the lung to deal with and distinguish between innocuous and pathogenic inhalants.
However, this distinction does not always occur. Airway tolerance is necessary to avoid
the development of allergic disorders, such as asthma, which is dominated by a patho-
logical expansion of Th2 and Th17 cells in the airways. By contrast, tumor cells induce
tolerogenic factors in their microenvironment to evade T-cell mediated anti-tumor-immune
responses. This review updates current understandings on the effect of the cytokines
TGF-β, IL-10, and IL-17A on the lung immune responses to antigen, and analyzes their
involvement in allergic asthma and lung cancer.The aim of the review is to evaluate where
therapeutic intervention may be feasible and where it might fail. The multifunctional role
of these cytokines further complicates the decision on the timing and concentration for
their use as therapeutical targets. In fact, TGF-β has suppressive activity in early tumori-
genesis, but may become tumor-promoting in the later stages of the disease. This dual
behavior is sometimes due to changes in the cellular target of TGF-β, and to the expan-
sion of the induced (i)-Tregs. Similarly, IL-17A has been found to elicit pro- as well as
anti-tumor properties. Thus, this pro-inflammatory cytokine induces the production of IL-6
which interferes with Treg development. Yet IL-17A could promote tumor growth in con-
junction with IL-6-dependent activation of Stat3. Thus, understanding the mechanisms of
airway tolerance could help to improve the therapy to both, allergic asthma and lung can-
cer. Hereby, asthma therapy aims to induce and maintain tolerance to inhaled allergens
and therapy against lung cancer tries to inhibit the tolerogenic response surrounding the
tumor.
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INTRODUCTION
The lung consists of two main components with distinct functions
and different immunological properties: the conducting airways
and the lung parenchyma. While the gas exchange takes place in
the lung parenchyma within its alveoli, the conducting airways
are covered with an epithelium skilled to perform a clearance of
inhaled antigens (Holt et al., 2008). The parenchyma lung surface,
Abbreviations: AHR, airway hyper-responsiveness; APC, antigen presenting
cell; BAL, bronchoalveolar lavage; BALF, bronchoalveolar lavage fluid; CCL11,
Chemokine (C–C motif) ligand 11; CXCR5, chemokine (C-X-C motif) receptor
5; DC, dendritic cell; ERK, extracellular signal-regulated kinase; FEV, forced expira-
tory volume; Foxp3, forkhead box protein 3; GSK-3β, glycogen synthase kinse-3β;
hMPV, human meta-pneumovirus; ICOS/ICOS-L, inducible T cell co-stimulator/-
ligand; IFN-γ, interferon-γ; IL, interleukin; iTreg, induced regulatory T cells; JAK1,
Janus kinase; MAP, mitogen-activated protein; MCh, Methacholine; MHC, major
histocompatibility complex; nat Treg, natural regulatory T cell; NSCLC, non-small
cell lung cancer; OVA, Ovalbumin; pDC, plasmacytoid dendritic cell; PI3K, phos-
phatidylinositol 3-kinase; RSV, respiratory syncytial virus; RV, Rhinovirus; TAK1,
transforming growth factor activated kinase; TAM, tumor-associated macrophage;
TGF-β, transforming growth factor β; TGF-βR, transforming growth factor β recep-
tor; Th, T helper cell; TIL, tumor infiltrating lymphocytes; TNF-α, tumor necrosis
factor α; Tr1/3, regulatory T cells type 1/3; TRAF, (TNF)-receptor-associated factor;
Treg, regulatory T cells.
by contrast, must be thin and permeable to allow an efficient gas
exchange. However, this permeability also causes a vulnerability
to infection (Brandtzaeg, 2009; Kohlmeier and Woodland, 2009).
As a result, the lung immune system must manage to protect the
host against pathogens, while maintaining tolerance to innocuous
antigens (Holt et al., 2008).
Immunological tolerance is generally defined as the unrespon-
siveness of the immune system to a certain antigen, mainly a
self-antigen or a harmless environmental antigen (Akbari et al.,
2001). A matter of special importance in diseases is the peripheral
tolerance to innocuous antigens that reach the respiratory tract by
inhalation, which is referred to as airway tolerance or respiratory
tolerance (Akbari et al., 2001). Immunological tolerance is gener-
ally indispensable to avoid overshooting responses to pathogens
and to prevent immune responses to self-antigens.
The immunological state of the lung is usually characterized by
a general hyporesponsiveness with a lack of functional allergen-
specific CD4+ T cells, down-regulation of the IgE production and
suppression of the development of airway hyper-responsiveness
(AHR) and inflammation (Holt et al., 2008). However, in predis-
posed individuals, an exposure of the lung immune system to an
antigen and its subsequent presentation by professional antigen
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presenting cells (APC) causes activation and pathological expan-
sion of subtypes of CD4+ T helper cells. In healthy individuals,
antigen presentation at first leads to activation and expansion of
CD4+ T cells as well. However, this is followed by removal and
inactivation of those antigen-specific T cells (Akbari et al., 2001).
Moreover, in subjects with a primary or secondary immunodefi-
ciency or patients with tumor, respiratory tolerance could result
in worsening of the disease.
This review primarily deals with the role of airway tolerance
for two typical lung diseases, namely allergic asthma and lung
cancer. Although these diseases are substantially different from
each other, they both seem to be associated with a dys-regulation
of the tolerogenic processes in the lung. Immunological para-
meters, which play a role for the induction of airway tolerance,
are inhibited in asthma patients and are up-regulated in lung
cancer patients. Consequently, there are parallels concerning the
molecular factors serving as potential targets for a therapeutic
approach to both diseases, although the general aim of asthma
therapy is an enhancement of airway tolerance, whereas anti-
cancer immune responses require circumvention of immunolog-
ical tolerance. According to that, we chose the three cytokines,
transforming growth factor β (TGF-β), IL-10, and IL-17A for
further discussion, focusing on their effects on asthma as well
as on lung tumor and their relevance as possible therapeutic
targets.
INDUCTION OF T CELL MEDIATED AIRWAY TOLERANCE
During the induction of airway tolerance, an initial exposure
of the airways to an innocuous antigen leads to activation and
expansion of antigen-specific T cells which is followed by the
recruitment of regulatory T cells (Tregs) to the lung mucosa and
a subsequent suppression of antigen-specific immune responses.
Further recognition of the same antigen by the lung immune sys-
tem does not lead to another effector cell expansion, but causes
the induction of an antigen-specific T cell tolerance (Figure 1).
This process is suggested to be primarily T cell-mediated, whereas
Forkhead box P3 (Foxp3)+ CD4+ CD25+ Tregs are considered
to play a prominent role for the underlying immunosuppressive
mechanisms (Holt et al., 2008). There is a distinction between
thymus-derived naturally arising Foxp3+ regulatory T cells and
Tregs, which are induced from naïve T cells and can acquire Foxp3
expression in response to specific tolerogenic stimuli, such as
TGF-β or retinoic acid (RA). Aside from that, there are other T
cell subtypes, which do not necessarily express Foxp3, but still
exhibit regulatory function, as for example Tr1 and Th3 cells
(Sakaguchi et al., 2008). Generally, Tregs represent a crucial fac-
tor for the regulation of peripheral T cell responses in virtually
all immunological fields. They are able to mediate clonal dele-
tion and anergy of effector T cells as well as suppression of
effector functions (Fontenot et al., 2003; Roncarolo et al., 2006;
Tang and Bluestone, 2008). Several mechanisms are proposed
to mediate Treg-dependent immunosuppression, as for exam-
ple cell-contact dependent inhibition and secretion of immuno-
suppressive cytokines, such as IL-10 or TGF-β (Ostroukhova
et al., 2004; Holt et al., 2008; Sakaguchi et al., 2008). How-
ever, the exact mechanisms underlying airway tolerance induc-
tion are still unclear. Noteworthy, animal studies demonstrated
FIGURE 1 | Induction ofT cell mediated airway tolerance. Innocuous
antigen reaches the respiratory epithelium where it is recognized by
resident airway mucosal dendritic cells (AMDCs). These DCs extend long
protrusions which enable them to sample the antigen directly from the
airway lumen. Afterwards, the AMDCs (including pDCs and mDCs) migrate
to the draining lymph nodes presenting the sampled antigen. Antigen
presentation by mDCs leads to an initial activation and expansion of
antigen-specific T cells. However, this is followed by inactivation and
deletion of these effector T (Teff) cells and the generation of regulatory T
(Treg) cells. This process also involves pDCs which contribute to the
induction of Treg cells as well. Treg cells mediate clonal deletion and anergy
of Teff cells in the draining lymph nodes as well as in the respiratory
mucosa where they are recruited to during tolerance induction. Alveolar
macrophages (AMs) contribute to airway tolerance via phagocytosis and
sequestration of incoming antigens. Moreover, they directly inhibit T cell
responses and seem to suppress dendritic cell migration as well as antigen
presentation. Treg cells, AMs, and pulmonary DCs each secrete
immunosuppressive cytokines such as IL-10 and TGF-β.
that Treg-mediated maintenance of airway tolerance seems to
require continuous exposure to airborne antigens, as antigen
withdrawal results in a decreased number of Tregs, going along
with an enhanced susceptibility to inappropriate Th2 cell depen-
dent immune reactions against respiratory antigens (Holt et al.,
2008).
Prior to the recruitment of Tregs to the respiratory mucosa
and the induction of T cell tolerance, the immune system of the
lung must recognize the incoming antigens and ensure that they
are not pathogenic. This process requires the interaction of innate
and adaptive immunity, whereas the identification of potentially
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pathogenic antigens is facilitated through pattern recognition
receptors, such as Toll-like receptors (TLRs) and involves the
action of pulmonary dendritic cells (Holt et al., 2008). The con-
ducting airways of the lung contain dense networks of specialized
dendritic cells underneath and within the epithelium, compris-
ing both myeloid DCs (mDCs) and plasmacytoid DCs (pDCs).
These so-called resident airway mucosal DCs (AMDCs) extend
long protrusions into the airway lumen through the intact epithe-
lium to directly sample inhaled antigens (de Heer et al., 2005;
Holt et al., 2008). Under non-inflammatory conditions, the main
function of AMDCs consists in a continuous uptake of inhaled
antigens and a subsequent migration to regional lymph nodes
(RLNs), where the harmless antigens are presented in a tolero-
genic manner (de Heer et al., 2005; Holt et al., 2008). Notewor-
thy, AMDCs lack the ability to efficiently present antigens, as
long as they reside in the lung mucosa, however they develop
this capability after the migration to the RLNs (Holt et al.,
2008). mDCs and pDCs both seem to contribute to the mech-
anisms which are involved in airway tolerance induction. Thus,
the presentation of innocuous antigens by mDCs induces activa-
tion and proliferation of antigen-specific naïve T cells, however,
instead of antigen-specific immunity this causes T cell tolerance.
This could possibly be explained by an incomplete activation
of mDCs under anti-inflammatory conditions resulting in an
abortive immune response, which means that either the antigen-
specific T cells are deleted or that Tregs are generated instead
of effector T cells (de Heer et al., 2005). In contrast to that,
the tolerogenic role of pDCs is primarily based on their ability
to induce the generation of Tregs. Moreover, pDCs have been
shown to produce indoleamine 2,3-dioxygenase (IDO), which
mediates inhibition of T cell proliferation. Finally, it has also been
demonstrated that airway tolerance induction is associated with
an increased production of IL-10 by lung DCs leading to sup-
pression of effector cell responses in the airways (de Heer et al.,
2005).
Beside Tregs and dendritic cells, alveolar macrophages also
contribute to the maintenance of immunological homeostasis in
the lung. In contrast to AMDCs, alveolar macrophages do not
migrate to the RLNs. Instead, the primary function of alveolar
macrophages during airway tolerance induction is the preven-
tion of adaptive immune responses mediated by phagocytosis and
sequestration of incoming antigens. Thus, alveolar macrophages
are suggested to directly inhibit T cell responses, using inhibitory
mediators, such as IL-10, TGF-β, prostaglandins, or nitric oxide.
However, there is also evidence that alveolar macrophages have
an influence on dendritic cell number and function, suppressing
antigen presentation as well as the ability of DCs to migrate to
RLNs (Holt et al., 2008).
The following paragraphs describe the molecular factors which
are involved in airway tolerance induction as well as their influence
on the development of allergic asthma and lung cancer. Consid-
ering the current knowledge on the mechanisms of respiratory
tolerance induction, the immunosuppressive cytokines TGF-β and
IL-10 might be of particular importance and will therefore be dis-
cussed in more detail. The third cytokine, which will be focused
on in this review, is IL-17A. In contrast to TGF-β and IL-10 it
is a pro-inflammatory cytokine and its role in airway tolerance
induction still needs to be elucidated. However, there is increasing
evidence that IL-17A plays an important role in the pathogenesis
of allergic asthma and lung cancer.
T CELL MEDIATED ALLERGIC ASTHMA
Asthma is a chronic inflammatory disease of the airways and is
characterized by chronic airway inflammation, increased mucus
production, reversible airway obstruction, remodeling of the air-
ways, and AHR. More than 300 million people worldwide suffer
from this disease and the number of affected people grows steadily.
To date, asthma is considered not-curable, however, there are
options to control this disease. On one hand asthma therapy con-
sists of so-called “controllers” such as long-acting β2-agonists and
steroids that need to be taken regularly to alleviate the symp-
toms and beware of or rather delay the exacerbation of asthma,
depending on the degree of the disease. On the other hand there
are therapeutics, known as “relievers”, including short-acting β2-
agonists which are used for the treatment of acute asthma attacks
to achieve an immediate bronchodilatation (Ukena, 2008). Nev-
ertheless, the major goal of asthma research remains to find a way
to cure this disease. There are various forms of asthma, including
allergic asthma, asthma induced by exposure to air pollution or
cigarette smoke and severe steroid-resistant asthma, also known
as allergic, non-allergic, and intrinsic asthma (Kim et al., 2010). In
this review we will focus on the most common form of asthma:
allergic asthma.
In healthy subjects, the respiratory confrontation with an
innocuous antigen first leads to a short-lived induction of a local
immune response to this antigen, followed by long-term periph-
eral tolerance (Lowrey et al., 1998). In asthmatic patients, harmless
antigens can provoke an unwanted Th2 sensitization to these
aeroallergens and cause Th2 responses (van Rijt et al., 2005).
Allergic asthma therefore has been found to be characterized by
a pathological expansion of at least Th2 cells and by the lack of
T regulatory cells. One hypothesis states that this could be due to
a lack of early childhood-exposure to infectious agents increasing
the susceptibility to allergic diseases by suppressing natural devel-
opment of the immune system (Umetsu et al., 2002). Th2 cells and
their cytokines are responsible for the recruitment of eosinophils
to the airways (IL-5) and for the allergen-specific development
of IgE (IL-4) (Umetsu et al., 2002). Furthermore, IL-9 and IL-13
have recently been found to be involved in the pathogenesis of
allergic asthma (Holgate and Polosa, 2008; Kim et al., 2010). It is
also known that lung DCs are necessary for the development of
Th2 cells during the establishment of airway inflammation seen
in allergic asthma (Kim et al., 2010). In contrast to that, Th1
cells are suggested to exhibit a regulatory function in the con-
text of allergic asthma as IFN-γ suppresses the differentiation of
Th2 cells. Thus, investigators show great interest in the Th1/Th2
balance to find new therapeutic modalities in asthma (Park and
Lee, 2010). Th17 cells are the third subset of T helper cells which
are also suggested to be relevant for the development of asthma,
although its particular role is not completely clear and requires
further investigation.
The overall objective of asthma research is to find a possibil-
ity to inhibit the exaggerated immune response found in asth-
matic patients. Hereby, airway tolerance inducing agents serve
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as promising targets for a potential vaccination strategy as air-
way tolerance is suggested to protect against and control the
onset of asthma by inducing T regulatory cytokines and other
mediators (Neurath et al., 2002). There are two main suppressor
cytokines that are released by regulatory T cells and concomitantly
are involved in their induction. As shown in Figure 2 these
two important cytokines released by Tregs control the patholog-
ical expansion of the Th2 and Th17 cells resulting in inhibition
of the downstream inflammatory response observed in allergic
asthma.
FIGURE 2 |T cell differentiation in allergic asthma. After allergen uptake
the DC migrates to the lymph node where it activates naïve T cells to
develop into different effector subsets. Allergic asthma has been found to
be characterized mostly by Th2 cell expansion and a lack of Treg cells. Th2
cytokines raise the production of allergen-specific immunoglobulin E (IL-4),
support the growth of eosinophils (IL-5) and mast cells (IL-9) and directly
cause airway hyperreactivity (AHR; IL-13). Furthermore, Th2 cells produce
IL-10 which is also expressed by eosinophils, DCs, and Treg cells, in
particular Tr1 cells which also require this cytokine for differentiation.
Non-asthmatic airways show a balance between Th1 and Th2 cells as IL-10
is able to suppress the differentiation of the Th1 subset by blocking IL-12
synthesis whereas the Th1 cytokine IFNγ contributes to the inhibition of
Th2 development. However, this balance is impaired in allergic asthma. The
Th1 subset is also supposed to have an inhibitory function on Th17 cells
which produce mainly IL-17A leading to the recruitment of eosinophils and
neutrophils to the airways. The development of Th17 cells depends on
IL-23 or TGF-β combined with either IL-6 or IL-21.TGF-β is produced by
eosinophils, DCs, and Treg cells whereas it is also required for the
induction of Treg cells and for the inhibition of the Th2 subset. Apart from
IL-10 and TGF-β, DCs also produce IL-27, an inhibitor of Th17 cells and an
inducer of Tr1 cell development. Except for DCs, this Treg subset is also
supposed to be involved in the induction of airway tolerance.
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THE ROLE OF TRANSFORMING GROWTH FACTOR-β IN ALLERGIC
ASTHMA
The profibrotic cytokine TGF-β exists in three highly homologi-
cal isoforms, TGF-β1, TGF-β2, and TGF-β3 (Halwani et al., 2011),
binding to the same receptor complex (Miyazono et al., 1994).
TGF-β is secreted as an inactive homodimer bound to a latent com-
plex (Makinde et al., 2007) which is targeted to the extracellular
matrix in association with TGF-β binding proteins. The final acti-
vation of the cytokine is achieved by several proteases, including
αvβ6 integrin, MMp-2, and -9, plasmin, thrombospondin-1, and
calpains (Makinde et al., 2007). According to Halwani et al. (2011)
also retinoids, tissue transglutaminases, reactive oxygen species,
and a low pH are involved in the TGF-β activation.
Transforming growth factor-β and other members of this fam-
ily are believed to be involved in the initiation, maintenance, and
resolution of inflammatory responses (Halwani et al., 2011). Their
importance in maintaining immune homeostasis has been demon-
strated using TGF-β knockout mice which exhibited multifocal
inflammatory lesions, especially in lungs and hearts, and died
within the first weeks of life (Shull et al., 1992; Kulkarni et al.,
1993).
Accordingly, TGF-β seems to play an important role for the
development of asthma as asthmatic patients show high levels of
TGF-β in the bronchoalveolar lavage fluid (BALF).
The cytokine is expressed and secreted in the lung by nearly
all structural immune cells as well as by inflammatory cells that
are recruited to the lung during asthma exacerbation. However,
eosinophils are believed to be the main source of TGF-β in asth-
matic airways (Ohno et al., 1992) and may play an important
role in airway remodeling. Halwani et al. (2011) demonstrated
that in severe asthma 65% of TGF-β1 mRNA positive cells were
eosinophils and that 75% of eosinophils were TGF-β1 positive.
In non-asthmatic individuals the main TGF-β source is the air-
way epithelium, but also fibroblasts, endothelial cells, vascular and
airway smooth muscle cells were reported to produce TGF-β.
T cells were identified as the central effector cells in TGF-β
mediated regulation of airway responses (Schramm et al., 2003).
TGF-β has an immunoregulatory role via its direct suppression of
T cell proliferation and macrophage activation. Over-expression
of TGF-β in T cells resulted in the suppression of allergic asthma
in a murine asthma model (Halwani et al., 2011). Moreover, adop-
tive transfer of Tregs over-expressing TGF-β were able to confer
complete resistance towards the induction of antigen dependent
airway hyperreactivity only in the presence of IL-10 indicating an
additive immunosuppressive role of these two cytokines (Presser
et al., 2008). In contrast, impairment of TGF-β signaling led to
increased allergic airway responses in transgenic mouse models
compared to wild-type mice (Schramm et al., 2003; Presser et al.,
2008).
One central role of T cells in airway inflammation is the pro-
duction of Th2 cytokines such as IL-4, IL-5, and IL-13. The latter
was increased in the BALF and sera of the Tg CD2-DNTGF-βRII
mice in a murine model of allergic asthma (Walter et al., 2001;
Schramm et al., 2003). These data indicate an inhibitory role of
TGF-β on IL-13 and consequently on AHR in a setting of aller-
gic asthma. Besides its anti-inflammatory effect, TGF-β is also a
pro-inflammatory cytokine. It is involved in the airway remodeling
process in asthma and other inflammatory and immune-mediated
lung diseases (Halwani et al., 2011). Furthermore, it exhibits antag-
onistic effects on epithelial cells. In fact, it either protects epithelial
cells from apoptosis through the Smad2/3 pathway or it induces
an apoptotic effect on these cells by activating the p38 mitogen-
activated protein kinase (MAPK) signaling pathway. The p38
MAPK pathway is activated upon stress or in response to chemical
agents (Makinde et al., 2007) and it is usually associated with cell
survival and proliferation. However, its activation in response to
TGF-βpromotes cell apoptosis (Makinde et al., 2007) which results
in the detachment of epithelial cells from the basement membrane
(Halwani et al., 2011). The increased epithelial damage facilitates
the development of an asthmatic phenotype. TGF-β is also able to
enhance the Fas-induced apoptotic and fibrotic effect in alveolar
epithelial cells. However, in the central airway epithelial cells TGF-
β induces an inhibitory effect on Fas-induced apoptosis (Makinde
et al., 2007). Additionally, the expression of TGF-β2 by bronchial
epithelial cells after challenge with IL-13 results in an increased
formation of mucin. Treatment with an antibody against TGF-β
caused a decrease in the number of mucus secreting goblet cells in
an asthmatic mouse model (Makinde et al., 2007). Furthermore,
mucus production and secretion is enhanced in fibroblasts due
to an increased expression of IL-6 induced by TGF-β (Makinde
et al., 2007). However, the expression of pro-inflammatory TGF-β
is resistant to the effects of corticosteroids (Halwani et al., 2011).
Taken together, these data indicate an anti-inflammatory function
of TGF-β when targeting T cells and a pro-inflammatory function
on airway epithelial cells and fibroblasts. Up to now, there exists
no satisfying treatment opportunity for allergic asthma. One of
the aims of allergen-specific immunotherapy is the induction of
peripheral T cell tolerance, which is characterized by the genera-
tion of allergen-specific Treg cells. Released by Tregs, TGF-β has
an anti-inflammatory effect. Besides inhibiting B-cell proliferation
and differentiation, TGF-β decreases immunoglobulins excluding
mucosal IgA (Fujita et al., 2012). However, Presser et al. (2008)
suggested that the suppressing capacity of TGF-beta overproduc-
ing Tregs on AHR is due to the concurrent release of IL-10, not
only TGF-β.
THE ROLE OF INTERLEUKIN-10 (IL-10) IN ALLERGIC ASTHMA
There is increasing evidence that IL-10-producing pulmonary
DCs play a very important role in airway tolerance. Akbari
et al. (2001) could already demonstrate that the adoptive trans-
fer of DCs from IL-10−/− mice could not induce OVA-specific
T cell unresponsiveness in recipient mice. IL-10 is an anti-
inflammatory and immunosuppressive cytokine with pleiotropic
effects in immunoregulation and inflammation. It is produced
by various cells such as B lymphocytes, NK cells, mast cells,
eosinophils, DCs, monocytes, macrophages, Tregs, and T lympho-
cytes. Among the T lymphocytes, Th2 cells seem to be the main
producers (Hofmann et al., 2012). Its role as immunomodula-
tory cytokine involves the inhibition of major histocompatibility
complex (MHC) class II expression, the reduction of CD80/CD86
mediated co-stimulation as well as the down-regulation of IL-1β,
IL-6, IL-8, TNF-α, and IL-12 production. Thus, three crucial func-
tions of specific and non-specific immunity, which are mediated
by monocytes and macrophages, namely antigen presentation,
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expression of immune mediators, and phagocytosis are affected
by IL-10 leading to the inhibition of airway inflammation (Sabat,
2010; Hofmann et al., 2012).
Accordingly, reduced levels of IL-10 have been found in the
lungs of asthmatic patients. Furthermore, IL-10 deficient mice
express higher levels of IL-4, IL-5, and IFN-γ compared to wild-
type littermates leading to the suggestion that normal levels of
IL-10 in healthy persons might be responsible for reduced Th2-
like immune responses (Umetsu and DeKruyff, 1999). However,
the role of IL-10 in allergic asthma is not clear. On one hand it
is thought to reduce AHR and inflammation on the other hand
it is suggested to be a crucial Th2 cytokine. Thus, IL-10 is able
to suppress the production of Th1 cytokines by blocking IL-12
synthesis (Umetsu et al., 2002). In addition, IL-10 is crucial for
the Th2-polarized responses in asthma and has a regulatory role
in the later immune responses by down-modulating the inflam-
mation caused by Th2 cell signaling as mentioned above (Umetsu
et al., 2002). Taking the mentioned findings together, the conclu-
sion arises that IL-10 plays an important role in asthma and airway
tolerance.
Pulmonary DCs are crucial for the maintenance of airway tol-
erance. For instance, they produce IL-10 after uptake of harmless
antigens, which is suggested to be involved in induction of Tregs,
in particular T regulatory type 1 (Tr1) cells. Akbari et al. could
confirm this statement by the adoptive transfer of IL-10 deficient
DCs (Akbari et al., 2001; Kushwah and Hu, 2011) in a murine
model of allergic asthma. The importance of IL-10-producing
DCs and Tr1 cells in the maintenance of airway tolerance could
also be demonstrated by an antibody-mediated blockade of IL-10
signaling (Gravano and Vignali, 2011).
Apart from IL-10, also IL-27 and TGF-β1 produced by pul-
monary DCs as well as ICOS/ICOS-L signaling seem to be
involved in the induction of Tr1 cells. In this term, the func-
tion of IL-27 is the stimulation of naïve T cells to express c-
maf, IL-21, and ICOS. Furthermore, IL-27 activates STAT1 and
STAT3 and thus drives IL-10 production in T cells (Murugaiyan
et al., 2009; Pot et al., 2009; Iyer et al., 2010; Kushwah and
Hu, 2011). Examination of the blood of allergic and healthy
donors indicated a down-regulation of antigen-specific Tr1 cells
and an up-regulation of IL-4 producing Th2 cells in allergic
patients. By comparison, in healthy subjects IL-10-producing
Tr1 cells are the predominant antigen-reactive T cell popu-
lation (Umetsu et al., 2002; Hammad and Lambrecht, 2008).
Thus, the induction of Tr1 cells and therefore IL-10 might be
a new therapeutical aim in the treatment of allergic asthma
since Tr1 cells inhibit airway hyperresponsiveness, amongst other
features of allergic asthma (Akbari et al., 2001; Umetsu et al.,
2002).
THE ROLE OF INTERLEUKIN-17 (IL-17) IN ALLERGIC ASTHMA
Recently, Th mediated immunity has enlarged to include a third
subset of effector helper T cells, the Th17 cells, termed after IL-
17A, their preferentially produced cytokine (Park and Lee, 2010;
Aujla and Alcorn, 2011). Beside Th17 cells, other cells such as
eosinophils, NK cells, neutrophils, NKT cells, and γδ T cells also
express IL-17A (Korn et al., 2009). It is already known that TGF-β,
a profibrotic cytokine which is also crucial for airway tolerance,
in combination with IL-6 or IL-21 drive the differentiation of
Th17 cells and therefore the production of the pro-inflammatory
cytokine IL-17A by inducing RORγt that is thought to be the mas-
ter regulator of Th17 cells. TGF-β in conjunction with IL-6 also
initiates the expression of IL-23 that in turn stimulates IL-17A pro-
duction. After binding to its receptor, IL-17A signals through two
different pathways, one of which is Act-1-dependent whereas the
second one is Act-1-independent. The Act-1-dependent pathway
includes intracellular signaling molecules such as TRAF6, TRAF3,
and TAK1 as well as members of the MAP kinase family such as
ERK and p38 leading to the secretion of neutrophil-mobilizing
molecules. The Act-1-independent one includes JAK1 and PI3K
and results in gene activation, cytokine secretion, and inactivation
of GSK-3β (Ivanov and Linden, 2009).
Several studies have shown that IL-17A is up-regulated in lung
tissues, BALF, sputum, and peripheral blood from patients with
allergic asthma. In addition, increased levels of IL-17A mRNA were
detected in the sputum of asthmatic patients where IL-17A levels
correlate with the number of neutrophils (Bullens et al., 2006; Park
and Lee, 2010). It has been shown that IL-17A causes neutrophilic
inflammation in allergic asthma via IL-8 as both IL-17A and IL-8
mRNA are increased in the sputum of allergic patients. Further-
more, IL-17A could enhance the development of neutrophils by
inducing the release of IL-6 from human bronchial fibroblasts
(Park and Lee, 2010; Aujla and Alcorn, 2011). An up-regulation of
IL-17A also seems to be linked to bronchial hyper-responsiveness
in asthmatic patients. However, the influence of Th17 cells on the
AHR is not yet completely clear as there are different findings on
this aspect in murine models of allergic asthma (Park and Lee,
2010; Aujla and Alcorn, 2011).
Apart from the contribution to neutrophilic inflammation
in asthma, IL-17A is also suggested to be responsible for the
eosinophilia observed in the airways of asthmatic patients. It is
assumed that IL-17A is able to synergize with IL-4 and IL-13 to
increase Th2 cytokines and CCL11 secretion (Aujla and Alcorn,
2011). Chemokine (C–C motif) ligand 11 (CCL11) belongs to
the CC chemokine family that is also known as eotaxin-1. CCL11
selectively recruits eosinophils by inducing their chemotaxis, and
therefore is implicated in allergic responses (Jose et al., 1994;
Garcia-Zepeda et al., 1996). It is obvious that the therapy of
asthma tend to eliminate inflammatory cells such as neutrophils
and eosinophils. As mentioned before, IL-17A seems to be involved
in the establishment and course of asthma and may offer a new
therapeutic target in the treatment of asthma.
Accordingly, blockade of IL-17A via anti-IL-17A antibody leads
to a down-regulation of IL-4, IL-5, and IL-13 as well as reduced
neutrophils and eosinophils in BALF as well as extenuated AHR in
an allergic model of this disease (Hellings et al., 2003; Anderson,
2008; Park and Lee, 2010). Furthermore, splenocytes of IL-17RA
deficient mice cultured with IL-25, a cytokine regulating allergen-
induced Th2 responses and AHR, lose their ability to produce IL-5
or IL-13 (Ballantyne et al., 2007; Kuestner et al., 2007; Rickel et al.,
2008; Park and Lee, 2010).
Other possibilities to target the IL-17A mediated effects are the
modulation of upstream (e.g., IL-6, IL-23) or downstream media-
tors (e.g., MAP kinases) of IL-17A. It is known that IL-23 is needed
for the development and stabilization of Th17 cells and therefore
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the IL-17A expression. Wakashin et al. (2008) could demonstrate
that it is possible to suppress the recruitment of lymphocytes,
eosinophils, and neutrophils after allergen sensitization using an
antibody against IL-23-p19. In addition, a down-regulation of
Th2 cytokines in murine lungs has been observed after OVA-
sensitization (Wakashin et al., 2008; Ivanov and Linden, 2009; Park
and Lee, 2010).
As mentioned before, another way to reduce IL-17A expres-
sion is the blockade of downstream messengers. Some groups
could already show that the blockade of p38 kinase and ERK
kinase results in a decreased expression of IL-6 and IL-8 from
human bronchial epithelial cells. These experiments also disclosed
a more potent effect of the p38 kinase inhibitor indicating that this
pathway is more promising as target (Ivanov and Linden, 2009).
Taken together, there are several alternatives to regulate IL-
17A expression representing new therapeutic strategies in the
treatment of asthma.
TOLERANCE AND LUNG CANCER
Lung cancer is the most common cancer-related cause of death
worldwide (van Klaveren, 2009). Despite many years of research,
there is still no efficient therapy against this disease. Since lung
cancer is described as almost symptom free during its early stages,
a large proportion of the patients already shows metastases by
the time of diagnosis. As a consequence, only 15% of the patients
survive for more than 5 years after primary diagnosis (van Klav-
eren, 2009; Reddy et al., 2011). Generally, lung cancer is thought
to arise upon a number of pre-neoplastic lesions in the airway
mucosa. There are two main types of lung cancer, namely small
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC),
whereas NSCLC is more common accounting for approximately
75% of all lung cancer cases (Ellis, 2012). NSCLC in turn involves
several subtypes such as adenocarcinoma (Ad), bronchoalveolar
carcinoma (BAC), squamous cell carcinoma (SCC), large cell car-
cinoma (LCC) as well as some mixed subtypes (Kerr, 2001; Ellis,
2012).
The predominant cause of lung cancer is tobacco smoking
explaining the fact that there is a higher incidence of this dis-
ease in developed countries (van Klaveren, 2009). However, an
increased lung cancer risk is also associated with inherited fea-
tures as well as exposure to various environmental carcinogens
such as asbestos, arsenic, radon, and polycyclic aromatic hydro-
carbons (Ellis, 2012). Apart from that, there is a close relationship
between the development of several kind of tumors and inflamma-
tion. However, the relationship between cancer and the immune
system is ambiguous. On one hand inflammation is associated
with production and secretion of tumor growth promoting mole-
cules such as DNA-damaging agents as well as particular cytokines
and growth factors, which are able to enhance cell prolifera-
tion. In accordance, chronic inflammation potentiates the risk of
tumor development (Muller and Scherle, 2006). Thus, patients
with chronic obstructive pulmonary disease have been shown to
have a higher risk of developing lung cancer (Reddy et al., 2011).
On the other hand inflammatory immune responses are sug-
gested to play a major role for tumor rejection. For instance,
immune-compromised Rag−/− and STAT1−/− mice show a sig-
nificantly higher incidence of tumor development (Mapara and
Sykes, 2004; Muller and Scherle, 2006). Although normally the
immune system is able to recognize particular tumor antigens,
for example mutated epitopes, cancer cell antigens are always
self-antigens, which strongly hampers the recognition of tumor
cells by the immune system (Perales et al., 2002). Moreover,
tumor cells have evolved numerous strategies to escape immune-
mediated rejection. For example, they may lack tumor-specific
antigens or co-stimulatory signals which are necessary to elicit
an adequate immune response. They also might show a reduced
expression of MHC class I, thereby avoiding recognition by
CD8+ cytotoxic T cells (CTLs). Finally, tumors seem to be
able to actively achieve immunosuppression by the production
of anti-inflammatory molecules such as the cytokines TGF-β
and IL-10, the enzyme indoleamine 2,3-dioxygenase (IDO) or
the inhibitory cell-surface protein programmed death ligand-1
(PD-L1) (Byrne et al., 2011). Besides, a general immunologi-
cal hyporesponsiveness and thus a suppressive microenvironment
as it exists in airway tissues could make an efficient anti-tumor
response even more difficult compared to other tissues. This could
probably potentiate the risk of tumor growth in the respiratory
tract resulting in diseases such as lung tumor (Karabon et al.,
2011). Taken together, this indicates that immunological toler-
ance, which normally serves to protect the host from dangerous
self-directed immune reactions, becomes a problem in connec-
tion with cancer diseases. For that reason, current approaches
to cancer therapy are often aimed at breaking self-tolerance,
thereby enhancing the anti-tumor immune response (Perales et al.,
2002).
The most important mediators of airway tolerance are sug-
gested to be Tregs which are suggested to hamper immune sur-
veillance and to inhibit efficient immune responses against can-
cer (Sakaguchi et al., 2008). Thus, it has been shown that at
early stages of cancer Foxp3+ Tregs accumulate at the tumor
site (Figure 3; Sakaguchi et al., 2008; Byrne et al., 2011). More-
over, there is an increased number of Tregs in the peripheral
blood of patients with NSCLC as well as other kinds of can-
cer diseases (Li et al., 2011; Onishi et al., 2012). An increased
ratio of Tregs to effector T cells at the tumor site seems to
correlate with poor prognosis for cancer patients (Byrne et al.,
2011; Onishi et al., 2012). Based on these assumptions, numer-
ous animal studies aimed to analyze the effects of Treg depletion
or an alteration of Treg function. The results of these studies
indicate that the elimination or a reduction of Tregs can break
immunological tolerance to tumor cells in vivo and in vitro and
induce an effective tumor-specific immune response (Shimizu
et al., 1999; Sakaguchi et al., 2008). For example, elimination of
Tregs and a concomitant stimulation of effector T cells resulted
in tumor rejection in 90% of sarcoma-bearing mice (Whelan
et al., 2010). In addition, the attempt to remove Tregs in can-
cer patients led to a regression of melanoma metastases (Rasku
et al., 2008). According to that, Tregs represent an obstacle for
successful immunotherapy against cancer (Byrne et al., 2011;
Onishi et al., 2012). Therefore, a promising target for future cancer
immunotherapy is to overcome Treg-mediated tumor cell toler-
ance. Although up to now the mechanisms of how Tregs inhibit
anti-tumor responses and why Tregs accumulate at tumor sites
have to be still elucidated (Li et al., 2011), there is evidence for
www.frontiersin.org July 2012 | Volume 3 | Article 216 | 7
Andreev et al. Airway tolerance in the lung
FIGURE 3 | Lung cancer-associated immunosuppressive
microenvironment. An efficient anti-tumor immune response strongly
depends on IFNγ-producing Th1 cells which in turn mediate the activation
of tumor-specific CD8+ cytotoxic T cells (CTLs) which are required for the
elimination of cancer cells. The lung immune system is characterized by a
general hyporesponsiveness and a suppressive microenvironment
inhibiting an efficient anti-tumor immune response. This involves, inter
alia, Treg cells, which have been found to accumulate at the tumor site
and the cytokines IL-10, TGF-β, and IL-17A. These cytokines can also be
produced by the tumor cells. Thus, it is possible that tumor cells
contribute to the induction of Treg differentiation or at least to the
recruitment of Treg cells to the tumor site. TGF-β suppresses T cell
proliferation and differentiation of naïve T cells into effector memory cells
as well as antigen presentation. Moreover, it is involved in the
development and function of induced Treg cells. The immunosuppressive
functions of IL-10 include the inhibition of Th1 cell proliferation and
cytokine production as well as the suppression of antigen presentation.
In addition, IL-10 is involved in Treg development and function, in
particular Tr1 cells. The tumor-promoting role of the Th17 cytokine IL-17A
can be attributed to its relation to the proto-oncogene Stat3. One
function of Stat3 is the inhibition of IL-12 expression which is required for
the induction of Th1 differentiation and thus anti-tumor immune
responses. The differentiation of Th17 cells requires the presence of IL-6
and TGF-β, whereas Treg development is induced by TGF-β alone and IL-6
promotes Treg inhibition. Nevertheless, IL-17A seems to be linked to Treg
development in tumor via a mechanism that is still unclear.
some Treg-associated molecules to be involved in these processes
such as TGF-β1 or IL-10. Moreover, recent data indicates that
IL-17A, a molecule previously described as a pro-inflammatory
factor, unexpectedly might also be connected to Treg mediated
tumor promotion (Li et al., 2011; Reppert et al., 2011; Onishi
et al., 2012).
THE ROLE OF TRANSFORMING GROWTH FACTOR-β IN LUNG CANCER
Transforming growth factor-β plays a central role for the regula-
tion of the balance between inflammation and tolerance in both
alveoli and the conducting airways of the lung. TGF-β influences
T cell proliferation and differentiation as well as T cell apoptosis
and antigen presentation (Cottrez and Groux, 2001). In partic-
ular, this cytokine suppresses the differentiation of naïve T cells
into effector memory cells and inhibits the proliferation of T
cells. Moreover, it is involved in development and function of
induced Tregs (iTregs). Thus, TGF-β exhibits typical features of
immunosuppressive cytokines indicating a tumor-promoting role
of TGF-β. However, besides its various immune regulatory func-
tions, TGF-β is also able to inhibit epithelial proliferation and to
induce expression of extracellular matrix components suggesting
that TGF-β might rather act as a tumor suppressor, inhibiting the
development and progression of cancer (Figure 3; Markowitz and
Roberts, 1996).
Previous studies concerning the role of TGF-β in lung cancer
revealed that lung cancer patients show increased serum levels
of TGF-β as compared to healthy individuals (Hasegawa et al.,
2001). Moreover, it has been shown that different kinds of tumor
cells, including small- as well as NSCLC cells, over-express TGF-β
(Wojtowicz-Praga, 2003; Jeon and Jen, 2010). Furthermore, vari-
ous types of cancers have been shown to require TGF-β activity
to form metastases (Roberts and Wakefield, 2003). These find-
ings indicate that TGF-β indeed supports tumorigenesis. However,
it has also been shown that higher levels of TGF-β in patients
with lung Ad are associated with better prognosis (Inoue et al.,
1995).
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This contradiction could possibly be explained by the fact
that the increased expression and activation of the TGF-β lig-
and during carcinogenesis is often accompanied by a decreased
expression or inactivation of the TGF-β receptors resulting in an
unresponsiveness of the tumor cells to TGF-β-induced growth
inhibition (Roberts and Wakefield, 2003; Jeon and Jen, 2010).
Thus, it has been reported that numerous tumor types are
characterized by the loss of functional RII or RI TGF-β recep-
tor due to somatic mutations (Markowitz and Roberts, 1996).
The consequence could be that the role of TGF-β for cancer
development changes in the course of tumorigenesis. Whereas
it exhibits tumor suppressor activity at early stages of tumor
development, it loses this function due to TGF-β receptor unre-
sponsiveness and becomes a tumor promoter in late-stage dis-
ease supporting tumor invasiveness and metastases (Roberts and
Wakefield, 2003; Jeon and Jen, 2010). Consistent with this idea,
studies on mammary tumors in mice revealed that enhanced
TGF-β signaling leads to a delayed development of primary
tumors but an increased formation of lung metastases whereas
a disruption of TGF-β signaling has the opposite effect lead-
ing to earlier appearance of primary tumors but a lower num-
ber of metastatic foci (Roberts and Wakefield, 2003). In con-
sideration of these facts, the disruption of TGF-β mediated
immunosuppression could be a promising therapeutic approach
to cancer.
THE ROLE OF INTERLEUKIN-10 (IL-10) IN LUNG CANCER
Interleukin-10 (IL-10) is a Th2 cytokine which has long been
associated with anti-proliferative properties. Its immunosuppres-
sive functions include the inhibition of Th1 cell proliferation and
cytokine production, the inhibition of antigen presentation and
natural killer cell activity as well as the down-regulation of tumo-
ricidal molecules (de Vita et al., 2000; Hatanaka et al., 2000; Teng
et al., 2011). In addition, IL-10 has been shown to be necessary
to induce the development of T regulatory 1 cells (Tr1) in vitro
and to be involved in the regulation of TGF-β responses, thus
supporting the suppressive effects of TGF-β (Groux et al., 1997;
Cottrez and Groux, 2001). A wide range of cell types is known to
produce IL-10, as for example macrophages [in particular tumor-
associated macrophages (TAMs)], B cells, T cells (especially Tregs),
and epithelial cells (Ouyang et al., 2011; Wang et al., 2011). Besides
that, IL-10 is also known to be produced and secreted by different
types of cancer cells, including lung cancer (de Vita et al., 2000;
Hatanaka et al., 2000; Mocellin et al., 2005).
These findings indicate that IL-10 could be involved in tumor
immunosuppression. To prove this assumption, numerous stud-
ies have been performed to further analyze IL-10 regarding lung
cancer. Thus, it could be demonstrated that NSCLC patients
show significantly elevated IL-10 mRNA as well as serum levels
as compared to healthy controls which has been shown to be
associated with poorer prognosis (Hatanaka et al., 2000). Fur-
thermore, metastatic cancer has been associated with higher IL-10
levels than cancer without metastases. In addition, there seems
to be a relation between IL-10 levels and therapeutic success as
a comparison of IL-10 levels in lung cancer patients treated with
either radiotherapy or chemotherapy revealed that IL-10 values
were significantly increased in non-responders, whereas they were
decreased in responders (Wojciechowska-Lacka et al., 1996; de
Vita et al., 2000; Hatanaka et al., 2000). Another study revealed
that NSCLC patients with late-stage disease (stage II, III, and IV)
show increased levels of TAM-derived IL-10 which is accompanied
by lymph node metastases, pleural invasion, and lympho-vascular
invasion (Figure 3; Wang et al., 2011).
Nevertheless, data concerning the role of IL-10 for tumor
progression are partially inconsistent. Thus, in contrast to the
above-mentioned results, some preclinical and clinical studies
suggest that IL-10 is important for tumor rejection. Accordingly,
there are indications that IL-10 expression is reduced in patients
with NSCLC and that this reduction could correlate with poor
prognosis (Lu et al., 2004; Mocellin et al., 2005). However, up to
now a connection between higher IL-10 levels and better survival
could not be shown (Teng et al., 2011). Despite these contradic-
tions, the immune-suppressive molecule IL-10 is an important
factor during the induction of airway tolerance and might be a
promising target for future approaches to lung cancer therapy.
Therefore, it is necessary to further define the role of IL-10 in lung
cancer.
THE ROLE OF INTERLEUKIN-17 (IL-17) IN LUNG CANCER
The role of IL-17A in cancer is controversial. On the one hand IL-
17A has pro-inflammatory functions. Thus, IL-17A recruits neu-
trophils and induces the production of IL-6, IL-8, tumor necrosis
factor-α (TNF-α), and IL-1β (Weaver et al., 2007). In contrast to
that, most of the cytokines which are assumed to promote tumor
development are anti-inflammatory cytokines, as for example IL-
10 or TGF-β, indicating that IL-17A might be important for tumor
rejection (Wang et al., 2009; Chen et al., 2010). According to that,
tumor growth has been shown to be increased in IL-17−/−mice in
case of MC38 sarcoma (Kryczek et al., 2009). Nevertheless, there
is growing evidence that IL-17A could rather act as a tumor pro-
moter. For instance, an increased number of IL-17A producing
cells have been detected in different types of cancer (Chen et al.,
2010). Furthermore, in patients with lung Ad the mRNA levels of
IL-17A as well as of the Th17 transcription factors RORα4 and
RORc2 have been shown to be significantly increased (Reppert
et al., 2011). In addition to that, IL-17A is suggested to be respon-
sible for an enhanced production of VEGF-C resulting in increased
lymphangiogenesis. Finally, IL-17A expression also correlates with
poor prognosis in NSCLC patients (Figure 3; Chen et al., 2010).
One explanation for the putative, tumor-promoting function
of IL-17A is that the expression and the function of this cytokine
are closely related to the proto-oncogene Stat3. On the one hand
Stat3 regulates the expression of IL-17A whereas on the other
hand IL-17A signaling in turn leads to an IL-6-dependent acti-
vation of Stat3 itself creating a positive feedback loop (Wang
et al., 2009). Stat3 is known to have tumor-promoting prop-
erties as its expression in tumor cells has been associated with
enhanced tumor cell survival, proliferation, and angiogenesis as
well as with an accumulation of Tregs and myeloid-derived sup-
pressor cells. Stat3 activates the expression of the anti-apoptotic
gene Bcl-XL as well as of IL-23, which has been reported to pro-
mote carcinogenesis also. Besides that, Stat3 inhibits the expres-
sion of IL-12 which is involved in anti-tumor responses via NK
cell activation and Th1 induction (Hatton and Weaver, 2009;
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Wang et al., 2009). Consistent with this, IL-17A-deficient C57/Bl6
mice are characterized by a reduced Stat3 activation, as well as
increased numbers of tumor infiltrating CD4+ and CD8+ T cells,
which produce higher amounts of IFN-γ as compared to wild-
type littermates. As a consequence, those IL-17A-deficient mice
showed a reduced tumor growth rate in case of B16 melanoma
as well as in case of MB49 bladder carcinoma (Wang et al.,
2009).
Interestingly, the differentiation of Th17 cells depends on the
concomitant action of IL-6 and the suppressive cytokine TGF-
β which is also necessary for the induction of Tregs. IL-6, in
turn, inhibits the development of Tregs suggesting that the dif-
ferentiation of Tregs and Th17 cells could be mutually exclusive
(Weaver et al., 2007). In contrast to this assumption, recent stud-
ies indicate that the differentiation of Th17 cells may even be
connected to the development of Tregs (Zhou et al., 2009; Rep-
pert et al., 2011). Thus, an up-regulation of Th17 cell lineage
transcription factors has been shown to correlate with increased
Foxp3 expression in patients with lung Ad. Moreover, blocking
of IL-17A in a mouse model of lung Ad resulted in a decrease
of Foxp3+ Treg numbers. This was accompanied by decreased
levels of IL-6 and TGF-β, increased numbers of IFN-γ and
TNF-α producing CD4+ T cells as well as a significant reduc-
tion of tumor growth (Reppert et al., 2011). As a conclusion
these findings strongly support the idea that IL-17A is involved
in tumor growth promotion. Therefore, anti-IL-17A treatment




Allergic asthma is characterized by a lack of Tregs and a patho-
logical expansion of Th2 cells. Furthermore, it is suggested that
there is an imbalance between Th1 and Th2 cells because under
normal circumstances Th1 cells are thought to have a regulatory
influence on Th2 cells. In addition, Th17 cells and especially their
main cytokine IL-17A seem to play a significant role in the patho-
genesis of asthma. Up to now, there is no therapy available to cure
this disease. Airway tolerance is thought to provide the possibility
to protect against and control the occurrence of asthma.
Transforming growth factor β is a pro- and anti-inflammatory
cytokine which is up-regulated in the BALF of asthmatic patients.
On the one hand it promotes airway remodeling and increases the
mucus production leading to an exacerbation of asthma. On the
other hand TGF-β, released by and acting on T regulatory cells, has
an immunoregulatory function. The cytokine is able to suppress
the proliferation of T cells and macrophages and therefore results
in suppression of allergic asthma. Thus, the induction of TGF-β
producing Tregs may represent a promising treatment in allergic
asthma.
Interleukin-10, an anti-inflammatory cytokine, was found to be
reduced in asthmatic patients. Simultaneously, Th2 cytokines were
up-regulated in these patients suggesting that IL-10 has a suppres-
sive effect on Th2 cells. There is increasing evidence that IL-10 and
Tr1 cells are essential for the development of airway tolerance. The
application of IL-10 as therapy has already been investigated in
diseases such as psoriasis or rheumatoid arthritis. In this first clin-
ical studies the data leads to the suggestion that IL-10 application
is rather adequate to prevent than to cure psoriasis (Asadullah
et al., 2003). These observations might also be true for allergic
asthma. But the role of IL-10 in allergic asthma and therefore new
treatment possibilities needs to be further elucidated.
Interleukin-17A is a pro-inflammatory cytokine which is up-
regulated in the lung of asthmatic patients. It seems to be linked
to neutrophilic and eosinophilic inflammation and perhaps also
to AHR. Therefore, it can be speculated that targeting IL-17A
is promising in asthma treatment. Investigators could already
demonstrate that blocking IL-17A per se or upstream regulators
and downstream messengers leads to reduced eosinophils, neu-
trophils, or Th2 cytokines. However, human studies are needed to
gain deeper insight into the immunological and pathogenic role
of IL-17A in allergic asthma.
LUNG ADENOCARCINOMA
Regulatory T cell numbers are found to be increased in lung can-
cer patients which has been associated with poor prognosis. Thus,
Tregs are thought to represent a predominant obstacle for the
induction of anti-tumor immune responses and lung cancer ther-
apy. Efficient anti-tumor immunity strongly depends on IFN-γ
producing Th1 cells, mediating the activation of tumor-specific
CD8+CTLs which are required for the elimination of cancer
cells. However, Tregs are suggested to antagonize these inflam-
matory effector cell responses (Byrne et al., 2011). It is possible
that tumor cells contribute to the induction of Treg differenti-
ation or at least to the recruitment of Tregs to the tumor site.
Although the potential underlying mechanisms are not identi-
fied yet, it has been reported that several tumor types, including
lung tumors, are able to produce considerable amounts of cer-
tain cytokines such as TGF-β, IL-10, or IL-17A. Interestingly, these
cytokines are suggested to be connected to Treg development or
function.
For instance, the immunosuppressive factor TGF-β is required
for the development of iTregs. However, its role for tumor immu-
nity is equivocal. Thus, it seems to show tumor suppressor activity
at early stages of tumor development. However, in the course
of tumor progression, cancer cells become insensitive to TGF-β
mediated suppression. As a consequence, TGF-β acts as a tumor
promoter in late-stage disease, probably due to its ability to induce
iTregs and to suppress the differentiation of naïve T cells into
effector T cells.
Another suppressive molecule, which is thought to be linked to
Treg function, is IL-10. This cytokine is necessary for the develop-
ment of T regulatory 1 cells (Tr1) and is involved in the regulation
of TGF-β responses. NSCLC patients show significantly elevated
IL-10 mRNA and serum levels as compared to healthy controls,
which has been shown to be associated with poorer prognosis.
However, data concerning the role of IL-10 for tumor progression
are also partially inconsistent. Thus, some preclinical and clinical
studies suggest that IL-10 might be important for tumor rejection,
meaning that the role of IL-10 for lung cancer still needs to be
elucidated.
The last molecule discussed in this review is IL-17A, which
generally is a pro-inflammatory cytokine. However, in contrast to
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former assumptions, the development of IL-17-producing Th17
cells and Tregs is not mutually exclusive, but rather seems to
be connected. According to this, blocking of IL-17A in a wild-
type mouse model of lung Ad resulted in a decreased num-
ber of Foxp3+ Tregs and an increase of IFN-γ and TNF-α
producing CD4+ T cells leading to a significant reduction of tumor
growth.
As a conclusion, the suppression of Tregs by blocking the sig-
naling pathways of particular cytokines may represent a promising
approach to future lung cancer therapy.
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